At the conclusion of this session, participants will be able to:
describe updated treatment guidelines
identify the latest drugs approved for hepatitis C virus (HCV) mono-infection and HCV-HIV co-infection
discuss medical problems common to HCV patients and the basics of care of the compensated cirrhotic patient
list new non-invasive modalities for assessment of liver damage
Target Audience: Clinicians, Fellows, HIV clinicians, Infectious diseases physicians, Members-in-training
Tracks: Adult ID, Epidemiology and Infection Control
Pre-Meeting Workshop Moderators:
Eliot Godofsky, MD, FIDSA, Bach and Godofsky
and
David Thomas, MD, MPH, FIDSA, Johns Hopkins University School of Medicine
Presentations:
8:00 AM
Introductory Remarks: Why Hepatitis C Needs ID Physicians
CME Credits: Maximum of 4 hours of AMA PRA Category 1 Credit™
ACPE Credits: ACPE 4 knowledge-based contact hours .40 of pharmacy CE
ACPE Number: 0221-9999-16-201-L02-P
Disclosures:
E. Godofsky,
AbbVie:
Consultant
and
Investigator
,
Consulting fee
and
Research grant
Gilead:
Investigator
,
Research support
Vertex:
Investigator
,
Research support
Janssen:
Consultant
and
Investigator
,
Consulting fee
and
Research support
Trek Therapeutics:
Investigator
,
Research support
Merck:
Investigator
,
Research support
Schering-Plough:
Grant Investigator
,
Research support
Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.